# Sources — Yul Brynner

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

Accessed November 3, 2026. The canonical source metadata and claim links are in `case.json`.

## Historical evidence

1. United Press International. Obituary, October 10, 1985. Supports that he was treated for lung cancer in Hanover, Germany, in September 1983 and said he would beat the disease and resume touring; that he died less than four months after his last performance as the King, a role he played 4,625 times over 34 years; that he died at 65 at New York Hospital-Cornell Medical Center of complications of cancer; and that he said he was born on Sakhalin on July 11, 1915. https://www.upi.com/Archives/1985/10/10/Yul-Brynner-exotic-actor/4761497764800/
2. United Press International. “Brynner's final bow,” October 10, 1985. Supports that he once smoked five packs of cigarettes a day, that he said in an interview he believed his cancer was directly caused by smoking (“It's suicide”), that his age was in dispute while he maintained he was born on July 11, 1920, and his farewell performance at the Broadway Theatre (dated July 2 in this report). https://www.upi.com/Archives/1985/10/10/Brynners-final-bow/6906497764800/
3. United Press International. “'Don't smoke, whatever you do',” February 19, 1986. Supports the American Cancer Society's 30-second television message taken from a January 1985 Good Morning America interview (“Now that I'm gone, I tell you: Don't smoke, whatever you do. Just don't smoke”), first shown on ABC about four months after his death. https://www.upi.com/Archives/1986/02/19/Dont-smoke-whatever-you-do/5599509173200/
4. Rochman S. Cancer Today (American Association for Cancer Research), December 5, 2011. Supports that in September 1983 he sought care after finding “a lump on his vocal chords,” that he had lung cancer and the tumor was too close to his heart for surgery, that he had smoked two to four packs a day from the age of 12 and quit in 1971, and that the public service announcement ran on the three major networks soon after his death. https://cancertodaymag.org/?p=547
5. TIME. Milestones, October 21, 1985. Supports 4,625 performances over 34 years, the Tony Award and Oscar, his death in New York after a two-year battle with cancer, and his own account of birth as Taidje Khan on Sakhalin. https://time.com/archive/6705008/milestones-oct-21-1985-4/
6. Biography.com. Yul Brynner. Supports his birth as Yuliy Borisovich Bryner on July 11, 1920, in Vladivostok, his Broadway debut as the King in 1951, the Academy Award for the 1956 film, and his death of lung cancer in New York City on October 10, 1985. https://www.biography.com/actors/yul-brynner
7. Encyclopedia.com (International Dictionary of Films and Filmmakers). Brynner, Yul. Supports a birth given as Taidje Kahn on Sakhalin Island, July 12, 1915, his varying accounts of his origins, his touring revival of The King and I to 1985, and the American Cancer Society message recorded shortly before his death. https://www.encyclopedia.com/movies/dictionaries-thesauruses-pictures-and-press-releases/brynner-yul
8. HISTMED Master Roster v3. Internal project source. Its clinical claims were provisional and were not treated as independent corroboration.

## Clinical guidance

1. CMID: Clinical Monitoring Intelligence Database (Aether Forge, 2026), lung cancer monograph. Broad molecular profiling (EGFR, ALK, ROS1, BRAF, KRAS including G12C, MET exon 14, RET, NTRK, HER2, NRG1) and PD-L1 at diagnosis of advanced nonsquamous NSCLC; immune-related adverse event labs (TSH, liver tests, glucose, cortisol) before each immunotherapy infusion; response imaging every 6 to 12 weeks on systemic therapy; dyspnea and cough, smoking status, distress, and fatigue at every visit; depression and anxiety screening; dietary review; dental evaluation on bone-modifying agents; vaccinations and other-cancer screening. https://patrickrutledge.github.io/topthirty/
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Tissue diagnosis, staging with PET-CT and brain MRI, biomarker testing before first-line therapy, first-line options for PD-L1 50 percent or more without an actionable alteration, bone metastases, and response assessment. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450
3. Schneider BJ et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. *J Clin Oncol* 2021;39(36):4073-4126. Baseline and per-cycle thyroid and liver tests, cortisol as indicated, and grade 1 rash managed with emollients, a topical corticosteroid, and an oral antihistamine while treatment continues. https://pubmed.ncbi.nlm.nih.gov/34724392/
4. Ferrell BR et al. Integration of Palliative Care Into Standard Oncology Care: ASCO Clinical Practice Guideline Update. *J Clin Oncol* 2017;35(1):96-112. Palliative care alongside active treatment, beginning within eight weeks of diagnosis of advanced cancer. https://pubmed.ncbi.nlm.nih.gov/28034065/
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Distress Management. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1431
6. Medicare Preventive Services reference (Aether Forge, 2026); U.S. Preventive Services Task Force A and B recommendations, including colorectal (2021) and prostate (2018) cancer screening, abdominal aortic aneurysm screening (2019), and depression screening (2023); CDC Adult Immunization Schedule by Age. https://patrickrutledge.github.io/preventative_services/

## Editorial resolutions

- **Recent-death rule.** Does not apply: Brynner died in 1985. The case still uses only published sources for history and attributes no statement or health fact to his relatives or colleagues. The interviewer to whom he described smoking as the cause of his cancer is not named. His spouse, company manager, and dresser in the modern episode are unnamed and say nothing.
- **Birth date.** The documented date is July 11, 1920, in Vladivostok (Biography.com), which agrees with his age of 65 at death in UPI and TIME. He gave other accounts himself: UPI reports that he said he was born on Sakhalin on July 11, 1915; a film reference gives July 12, 1915, as Taidje Kahn; TIME repeats the Sakhalin account. The case keeps July 11, 1920, at day precision and records the 1915 dates as conflicting alternatives. Citizenship details were not verified in a fetched source and are not used; the nationality is the roster's “Russian-born American.”
- **Diagnosis and course.** Sources agree that lung cancer was found in September 1983 and that the tumor could not be removed surgically (Cancer Today: “too close to his heart for surgery”). Cancer Today says a vocal-cord problem led to the diagnosis; the case models this as hoarseness from left vocal fold paralysis caused by aortopulmonary window disease, a recognized presentation, and does not model a laryngeal tumor. UPI places his September 1983 treatment in Hanover, Germany; a search result attributing treatment to Los Angeles could not be fetched and is not used. His 1983 treatment itself is not modeled. He returned to the stage and played the King until summer 1985 (UPI's “final bow” gives July 2; other accounts give June 30), less than four months before his death.
- **Anti-smoking message.** UPI (1986) reports the American Cancer Society message first aired on ABC in February 1986, about four months after his death; Cancer Today says networks ran it within days of his death. Both are recorded; neither date enters the episode. The smoking amounts differ (five packs a day at one time in UPI; two to four packs from age 12 in Cancer Today). The modern pack-year estimate (about 115) is a synthetic midpoint, and the quit year 1971 is from one source. Smoking claims are marked sensitive.
- **Index age and dates.** The modern episode presents Brynner at 63, at the documented diagnosis. The synthetic date of birth is July 11, 1963 (shift 43 years). The index visit on September 1, 2026 maps to September 1, 1983; the PET-CT and brain MRI (September 4), biopsy (September 9), consultation visit (September 15), treatment start (September 22), palliative care visit (September 29), voice injection (October 6), cycle 2 (October 13), sick visit (October 20), and preventive visit (October 27) map to the same days of 1983. Every date is in his lifetime and in the months of the documented diagnosis. Past medical history holds only the smoking history.
- **Synthetic clinical picture.** The histology (adenocarcinoma), stage (cT4 N2 M1c, IVB), bone metastases, PD-L1 70 percent, KRAS G12V and TP53 without an actionable alteration, pembrolizumab, zoledronic acid, laboratory results, and voice procedure are synthetic. Judgment calls: (1) bone metastases make first-line systemic therapy the standard, as the teaching objective requires; real 1983 records of spread were not used; (2) treatment waits for tissue sequencing even though plasma testing was negative, to teach the NCCN sequence; (3) pembrolizumab alone rather than with chemotherapy, a preferred option at his PD-L1 level, chosen with him to protect his energy and voice for work; (4) zoledronic acid is started with cycle 2 so a first-dose reaction is not confused with an early immune-related event.
- **Sick visit.** A same-day visit on October 20, 2026 for an itchy maculopapular rash three and a half weeks after the first dose: grade 1 immune-related dermatitis, with normal thyroid, liver, and kidney tests and mild eosinophilia; treated with a topical corticosteroid, an antihistamine, and emollients while pembrolizumab continues, per ASCO 2021. It interacts with his treatment and does not suggest any undocumented real illness.
- **Focused visits.** The three chronic-care follow-ups (diagnosis and staging review, treatment start, and cycle 2) are documented as focused visits on the CMID lung cancer monograph with NCCN, ASCO immune-related adverse event, ASCO palliative care, and NCCN distress guidance, each listing every item the protocol calls for at that point with its interval and status. Protocol deviation recorded instead of an invented result: the distress and symptom screen was not done at the treatment-start visit, a key transition, because the visit ran long; the palliative care team assessed him a week later, the next scores were lower, and screening moved to check-in. A divergence is recorded rather than a deviation: the CMID lists cortisol before each infusion, while ASCO 2021 checks it at baseline and for symptoms; with a normal baseline and no symptoms, it was not repeated at cycle 2.
- **Consultation.** The thoracic oncology referral and the consultation by Leah Morrow, MD (a fictional consultant), on September 15, 2026, are **S**. The consultant answers all six questions in line with what the record shows happened afterwards: stage IVB confirmed without biopsy of the bone lesions; therapy deferred until tissue sequencing, reported a week later; pembrolizumab started on September 22; the laboratory schedule followed before each cycle; zoledronic acid started with cycle 2 after the dental examination; palliative care two weeks after diagnosis; and voice injection and therapy before a graded return to work.
- **Adult preventive visit.** On October 27, 2026 (true frame October 27, 1983), at 63, so `preventive_adult`. Vaccines are the priority (influenza, PCV20, and recombinant zoster dose 1 given; COVID-19 and RSV due); colorectal screening and the statin decision are left due by shared decision until the first response scan; he declined PSA testing. Advance care planning names an unnamed health care agent and records his priorities (working on stage as long as he can, plain information, full cancer treatment now) and no other treatment preference.
- **Not used.** His 1983 treatment, his last months, hospital details, and any account by family members or colleagues. The roster's summary was not used as independent evidence.
